TRex Bio, Inc. — Form SCHEDULE 13D
Filed October 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 22/100
What the filing says
SV Biotech Crossover Opportunities Fund LP, managed by SV BCO I GP LLP (Boston-based VC firm with partners Michael Ross, Nikola Trbovic, Catherine Bingham, and Jamil Beg), filed a joint Schedule 13D on October 16, 2026, regarding common stock in TRex Bio, Inc. The filing discloses investment committee members and a joint filing agreement but does not specify the stake size, dollar amount invested, or percentage ownership.
Why this rating
Standard Schedule 13D disclosure by VC fund; no stake size, ownership %, or acquisition details disclosed. Routine filing without material transaction specifics.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.